Belite Bio (NASDAQ:BLTE) Insider Sells $331,980.00 in Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Hendrik Scholl sold 2,000 shares of the company's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $165.99, for a total transaction of $331,980.00. Following the transaction, the insider owned 12,500 shares of the company's stock, valued at $2,074,875. This represents a 13.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Hendrik Peter Scholl also recently made the following trade(s):

  • On Thursday, October 1st, Hendrik Scholl sold 500 shares of Belite Bio stock. The stock was sold at an average price of $165.32, for a total transaction of $82,660.00.

Belite Bio Stock Down 1.1%

BLTE stock opened at $162.56 on Tuesday. The stock has a market cap of $6.55 billion, a PE ratio of -59.55 and a beta of -1.19. The firm's 50-day simple moving average is $160.26 and its 200 day simple moving average is $160.22. Belite Bio, Inc. Sponsored ADR has a fifty-two week low of $105.88 and a fifty-two week high of $200.00.




Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.19. Equities analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BLTE shares. Cantor Fitzgerald lifted their price target on Belite Bio from $266.00 to $270.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Zacks Research downgraded Belite Bio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Belite Bio in a report on Friday, October 2nd. Jefferies Financial Group reissued a "hold" rating on shares of Belite Bio in a report on Wednesday, September 9th. Finally, Morgan Stanley raised their target price on Belite Bio from $201.00 to $206.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Belite Bio presently has a consensus rating of "Moderate Buy" and an average target price of $226.91.

View Our Latest Research Report on BLTE

Institutional Investors Weigh In On Belite Bio

Institutional investors have recently bought and sold shares of the stock. Great Point Partners LLC bought a new position in Belite Bio in the 3rd quarter valued at about $12,736,000. Marshall Wace LLP acquired a new position in Belite Bio during the 3rd quarter valued at about $15,282,000. State Street Corp increased its stake in Belite Bio by 6.9% during the 3rd quarter. State Street Corp now owns 34,044 shares of the company's stock valued at $5,781,000 after buying an additional 2,196 shares during the period. Alberta Investment Management Corp bought a new stake in shares of Belite Bio during the 3rd quarter worth about $4,076,000. Finally, Candriam S.C.A. bought a new stake in shares of Belite Bio during the 3rd quarter worth about $10,711,000. Institutional investors and hedge funds own 0.53% of the company's stock.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Featured Articles

Insider Buying and Selling by Quarter for Belite Bio (NASDAQ:BLTE)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Belite Bio?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Belite Bio and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles